NEUROSOLVE^®

Vitreoretinal Technologies, Inc. is in clinical development of Neurosolve as a neuro-protector for preventing the progression of glaucomatous optic nerve damage.
READ MORE >>

VRT is also in clinical development of Neurosolve^® as a retinal stimulant as a treatment for the progression of dry age related macular degeneration (ARMD).
READ MORE >>

Neurosolve is also in clinical development for treatment of retinitis pigmentosa.
READ MORE >>